Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation develops and supplies blood-safety technologies and pathogen-protected blood components for blood centers and hospitals. Its recurring news centers on the INTERCEPT Blood System for platelets and plasma, the U.S. INTERCEPT Blood System for Cryoprecipitation used to produce INTERCEPT Fibrinogen Complex, and the company’s red blood cell pathogen-reduction program.
Company updates commonly cover product revenue, gross margin trends, revenue guidance, government contract activity, international supply agreements, clinical studies involving pathogen-inactivated platelets, regulatory and pipeline developments, healthcare conference participation, and governance changes. Commercial disclosures often emphasize demand for INTERCEPT Fibrinogen Complex and adoption of pathogen inactivation technologies by blood establishments in the United States, Europe and other markets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cerus Corporation (CERS) will release its first quarter 2023 financial results on May 4, 2023, after market close. A conference call and webcast will follow at 4:30 P.M. ET for management to discuss results and provide an outlook.
The company focuses on safeguarding the global blood supply with its INTERCEPT Blood System, which is the only pathogen reduction system approved by both CE and FDA for platelets and plasma. The red blood cell system is under review in Europe and in late-stage clinical development in the US. Additionally, the INTERCEPT system for Cryoprecipitation is approved in the US for producing therapeutic products addressing bleeding issues related to fibrinogen deficiency.
Cerus Corporation (Nasdaq: CERS) reported strong fourth quarter 2022 revenue of $51.3 million, a 2% increase year-over-year, with product revenue rising 10% to $44.0 million. Full-year 2022 product revenue reached $162.0 million, up 24% from 2021. Despite a dip in government contract revenue by 29% in Q4, the company reiterated its 2023 product revenue guidance of $165-170 million. Product gross profit hit a record high of $24.5 million, reflecting a margin of 55.7%. Operational expenses rose by 11% in Q4 to $41.8 million, while the net loss for Q4 was $13.6 million. As of December 31, 2022, Cerus had $102.2 million in cash and equivalents.
Cerus Corporation (NASDAQ: CERS) will release its fourth quarter and full year 2022 financial results on February 28, 2023, after market close. A conference call is scheduled for 4:30 PM ET that same day, where management will discuss the results and provide a business outlook. The live webcast can be accessed via the Investor Relations page on the Cerus website. A replay will be available approximately three hours post-call until March 14, 2023. Cerus is focused on ensuring the safety of the global blood supply, offering advanced technologies like the INTERCEPT Blood System.
Cerus Corporation (CERS) announced its participation in two upcoming investor conferences. CEO William ‘Obi’ Greenman will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 14-15. He, along with CFO Kevin Green, will partake in a fireside chat at Cowen’s 43rd Annual Health Care Conference on March 8 at 1:30 PM EST, with a live webcast available at this link. Cerus, based in Concord, California, is focused on securing the global blood supply, offering the only pathogen-reduction system for platelets and plasma with CE mark and FDA approval.
Cerus Corporation reported preliminary product revenues for Q4 2022 of $44.0 million, a 10% increase from Q4 2021. Full-year 2022 revenue was $162.0 million, reflecting a 24% year-over-year growth, aligning with their guidance. For 2023, Cerus anticipates revenues between $165-$170 million. The CEO, William Greenman, highlighted continued demand for the INTERCEPT Blood System and acknowledged macroeconomic uncertainties affecting operations. Full financial results will be disclosed in late February.
Cerus Corporation (NASDAQ: CERS) announced that its COO, Vivek Jayaraman, will participate in two upcoming conferences. He is scheduled to present at the Stifel 2022 Healthcare Conference on November 16 at 1:50 p.m. EST in New York and at the Stephens Annual Investment Conference on November 17 at 12:00 p.m. EST in Nashville, TN. To access the webcasts, visit ir.cerus.com. Cerus is focused on ensuring the safety of the global blood supply with its INTERCEPT Blood System, already approved in various regions.